Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease. Update July/August 2023

Rothschedl, E. and Grössmann, N. (2023): Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease. Update July/August 2023. Fact Sheet Nr. 144.

[thumbnail of Fact Sheet Nr.144_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
144kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WR Dermatology
Language:	English
Series Name:	Fact Sheet Nr. 144
Deposited on:	21 Aug 2023 14:43
Last Modified:	17 Nov 2023 15:46

Repository Staff Only: item control page